Richard Scolyer, a renowned melanoma pathologist, is battling an aggressive grade 4 IDH-wildtype glioblastoma using a pioneering immunotherapy approach. Diagnosed after experiencing a seizure in May 2023, Scolyer, who is also co-Australian of the Year, is testing a novel treatment strategy developed by his colleague Georgina Long at the Melanoma Institute Australia.
Long, who had previously achieved success using immunotherapy for melanoma patients, adapted the approach for Scolyer's brain cancer. The treatment involves administering a combination of immunotherapy drugs intravenously before surgery, with the goal of stimulating Scolyer's immune system to recognize and destroy the tumor cells. This approach is based on the observation that immunotherapy drugs are more effective when given prior to tumor removal.
Radical Treatment Plan
The treatment plan was considered radical due to the high risks involved, including a 60% chance of fatal side effects such as severe brain swelling. Despite the odds, Scolyer chose to proceed, hoping for even a small chance of survival. Following the initial infusions, Scolyer underwent a six-hour surgery performed by neurosurgeon Brindha Shivalingam to remove pieces of the tumor.
Promising Early Results
Pathology results following the surgery revealed that Scolyer's immune cells were activated and appeared to be attacking the tumor cells. Scolyer described this as a "phenomenal result," suggesting a potential new frontier for brain cancer treatment. However, he emphasized the need for further clinical trials to definitively prove the treatment's effectiveness.
The Future
After nine infusions, Long decided to halt the immunotherapy. As of now, there are no signs of recurrence, but continuous monitoring is necessary. Scolyer remains hopeful that the scientific data gathered from his case will provide valuable insights and encourage further exploration of immunotherapy for brain cancer. He reflects on how this experience has shifted his priorities, emphasizing the importance of family and love.
